Metraipolis › archive › dc_8a75ac2326db

Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE… — Europe PMC PMID:40704669

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40704669
DOI
10.1093/ecco-jcc/jjaf138
License (as archived)
solo-consultazione
Archived
2026-11-10T05:16:56.286Z
SHA-256 of the archived text
c047b83119e90f7c34bc53c28d01d43fa42c872ff543a4fd0c999321db1ccd29
Stable URL of this page
https://metraipolis.com/documento/dc_8a75ac2326db

How to cite

Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE… — Europe PMC PMID:40704669 — Europe PMC (en), https://europepmc.org/article/MED/40704669 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a75ac2326db (Metraipolis archive dc_8a75ac2326db, sha256 c047b83119e90f7c34bc53c28d01d43fa42c872ff543a4fd0c999321db1ccd29)
BibTeX
@misc{dc8a75ac2326db,
  title = {Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE… — Europe PMC PMID:40704669},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40704669},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a75ac2326db; sha256 c047b83119e90f7c34bc53c28d01d43fa42c872ff543a4fd0c999321db1ccd29},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40704669. Agents can read the archived copy with the MCP tool read_document.